TAK 831

Drug Profile

TAK 831

Alternative Names: TAK-831

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda
  • Class Antipsychotics
  • Mechanism of Action D amino acid oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ataxia; Schizophrenia

Most Recent Events

  • 25 Jul 2017 Takeda plans a phase I trial in Healthy volunteers in USA (NCT03224325)
  • 21 Jul 2017 Takeda initiates enrolment in a phase I trial in Healthy volunteers in USA (PO) (NCT03224325)
  • 10 Jul 2017 Takeda plans a phase II trial for Friedreich's ataxia (PO) (NCT03214588)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top